BOSTON, August 21, 2024–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half year results for the six months ended June 30, 2024 on Wednesday, August 28, 2024.
A presentation and conference call for analysts and shareholders will be held at 9:00 a.m. EDT (2:00 p.m. BST) on the day of the announcement. A webcast of the presentation will be available on the Company’s website at https://investors.puretechhealth.com/events-presentations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company committed to developing new classes of drugs to transform the lives of patients with devastating diseases. The Company has created a broad and deep pipeline, driven both internally and through its incubated companies, through its experienced R&D team and extensive network of scientists, clinicians and industry leaders. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapy candidates, including two that have received both U.S. FDA and European marketing approval and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its incubated companies in various indications and stages of clinical development, including pivotal trials. All of the underlying programs and platforms that have led to this pipeline of therapeutic candidates were initially identified or discovered and then advanced through key validation points by the PureTech team.
For more information visit www.puretechhealth.com or contact us via X (formerly Twitter) @puretechh.
Cautionary note regarding forward-looking statements
This press release contains statements that are, or may be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release should be considered forward-looking statements, including, without limitation, those relating to PureTech’s development plans and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance or achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC, and our other regulatory filings. These forward-looking statements are based on assumptions regarding the Company’s current and future business strategies and the environment in which it will operate in the future. Each forward-looking statement speaks only as of the date of this press release. Except as required by law or regulation, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View original version on businesswire.com: https://www.businesswire.com/news/home/20240820540519/en/
Contacts
PureTech
Public relations
[email protected]
Investor information
[email protected]
Media from the UK and the EU
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
[email protected]
US media
Nichole Bobby
+1 774 278 8273
[email protected]
